For those who have sickle cell disease, there are only a few treatment options, which include bone marrow transplants, gene therapy or other treatments that address a subset of symptoms. Now, researchers report discovery of a small molecule that could treat sickle cell disease by boosting levels of fetal hemoglobin, a healthy form that adults normally do not make. The researchers will present their results today at ACS Spring 2021.
Ion channel activity varies according to the mechanical stresses acting on ion channels within the cell membrane, but directly measuring such changes within a complex cell membrane is difficult. Now, researchers at the University of Fukui have developed a simplified model system that allows experimenters to measure both membrane tension and the associated variability in ion channel activity. Their experiments have already yielded evidence for hysteresis in a potassium channel's responses to membrane tension.
Tokyo Medical and Dental University (TMDU) researchers prepared a nanomicelle delivery system to transport BDNF mRNA to the site of ischemic injury. The nanomicelle successfully produced BDNF and prevented the death of neurons when dosed 2 days after ischemia in rats. Long-term experiments showed significant improvements in memory compared with untreated rats. The findings are expected to extend the potential treatment window for preventing neuronal death after ischemic attack, and significantly improve outcomes for patients.
Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime. While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders, and offers a promising blood test aimed at a precision medicine approach to treatment.
Osaka University researchers have developed a single-crystal cobalt phosphide nanorod catalyst for the reductive amination of carbonyl compounds to primary amines. The nanorod catalyst performed better than conventional catalysts, was stable in air, and was effective under mild conditions. Additionally, it could be reused multiple times without loss of activity. It is hoped that the nanorod catalyst will provide a green and sustainable alternative for the synthesis of valuable products such as pharmaceuticals.
Spread of Candida auris on skin--a source of deadly infections--can be effectively stopped, according to new Case Western Reserve University research
On the first day of the UK campaign for COVID-19 vaccination, there were reports of two cases of anaphylaxis--a severe, potentially life-threatening allergic reaction--within minutes of administration of the Pfizer/BioNTech mRNA vaccine. Subsequently further cases of suspected anaphylaxis to the Pfizer vaccine were reported. A new report published in Clinical & Experimental Allergy reveals that an allergy to the ingredient polyethylene glycol (PEG) is a cause of anaphylaxis to the vaccine. However, this is in the context of millions of doses safely administered.
New research published in the British Journal of Pharmacology indicates that two currently available medications--an antifungal drug and an antidepressant--can effectively inhibit the virus that causes COVID-19 in laboratory cells.
Employing innovative technologies for combining data from hundreds of crystals, scientists determined the molecular structure of Glycine Transporter 1, a protein that modulates neuronal activity in the brain. The revealed binding sites through which the transporter can be inhibited by drugs. This could open new avenues for developing psychiatric drugs. The study was conducted by researchers at the European Molecular Biology Laboratory (EMBL) Hamburg, Aarhus University, F. Hoffmann-La Roche, Linkster Therapeutics, and University of Zurich.
New research could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.